共 564 条
[1]
Krasopoulos G(2008)Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis BMJ 336 195-198
[2]
Brister SJ(2020)Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysis J Neurol 267 3021-3037
[3]
Beattie WS(2017)Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for pharmacogenetics-guided warfarin dosing: 2017 update Clin Pharmacol Ther 102 397-404
[4]
Buchanan MR(2008)Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests Platelets 19 119-124
[5]
Lim ST(2007)A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Eur Heart J 28 1702-1708
[6]
Thijs V(2016)Synergistic inhibition of both P2Y1 and P2Y12 adenosine diphosphate receptors as novel approach to rapidly attenuate platelet-mediated thrombosis Arterioscler Thromb Vasc Biol 36 501-509
[7]
Murphy SJX(2004)Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor Biochem Pharmacol 68 1995-2002
[8]
Fernandez-Cadenas I(2002)2-Chloro N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate is a selective high affinity P2Y(1) receptor antagonist Br J Pharmacol 135 2004-2010
[9]
Montaner J(1996)A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents N Engl J Med 334 1084-1089
[10]
Offiah C(2019)A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease Thromb J 17 11-512